View ValuationTheralink Technologies 将来の成長Future 基準チェック /06現在、 Theralink Technologiesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 16Theralink Technologies Files Form 15Theralink Technologies, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.0001 per share.お知らせ • Feb 16Theralink Technologies, Inc. announced delayed 10-Q filingOn 02/15/2024, Theralink Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 04Theralink Technologies, Inc. Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor BoardTheralink Technologies, Inc. announced that their long-standing, strategic partnership with the Inova Schar Cancer Institute is beginning to deliver promising results by way of assessing the feasibility and impact of the actionable information provided by the Theralink assay into Inova's Molecular Tumor Board (MTB)-based treatment decisioning making for cancer patients. The partnership involves the integration of the Theralink assay, protected by ten patents, into Inova's molecular tumor board's operational workflow. Over the past year, Inova has undertaken a feasibility study to develop and implement the procedures and infrastructure necessary for proteomic analysis within the context of the Inova Schar Molecular Tumor Board. The Theralink assay provides a direct means of determining the actionability of genomic derangements identified, as well as directly measuring the activation/elevation of protein drug targets otherwise missed by genomic analysis alone. Thus, the incorporation of key phosphoprotein and protein data generated by Theralink's RPPA technology into the Inova MTB could synergize with current genomics analysis to produce more accurate treatment selection and patient-tailored therapy regimes. Interim results of this pan-tumor study were presented at the 2023 ASCO Conference in Chicago. Specifically, the analysis examined the feasibility of incorporating laser capture microdissection (LCM) enrichment of tumor specimens and reverse phase protein array (RPPA) analysis with next generation sequencing (NGS) into a molecular tumor board for improving selection of targeted cancer therapy. Integrated review of the RPPA and NGS data by the MTB supported a clinical recommendation change for over half of the patients overall. Further, the proteomics data from the Theralink assay provided additional treatment considerations for 59% of the patients, the outcomes for whom continue to be monitored. Moreover, the collaboration with Inova and their MTB resulted in a recent finding1 wherein the Theralink proteomics data revealed a specific mechanism of resistance and likely lack of benefit to a targeted therapy being considered by the MTB for a patient with a rare form of inflammatory myofibroblastic cancer. Lastly, Inova and Theralink presented the results of another important study at ASCO 2023 that focused on Theralink's unique ability to quantitatively measure HER2 abundance and activation and found that nearly 50% of pancreatic tumor actually express moderate amounts of HER2 protein, which could be missed by existing commercial HER2 assays. While HER2 expression is not routinely evaluated in clinical practice for pancreatic cancer these results may have clinical implications, especially as new classes of HER2 antibody drug conjugates are considered for patients with HER2 non amplified tumors across organ sites. Theralink and Inova will update findings and results post study completion. Published results are anticipated in early 2024.お知らせ • Aug 17Theralink Technologies, Inc. announced delayed 10-Q filingOn 08/15/2023, Theralink Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 28+ 1 more updateTheralink Technologies, Inc. Appoints Mick Ruxin as Chief Medical OfficerTheralink Technologies, Inc. announced the appointment of Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company’s President and Chief Operating Officer since December 2022, will assume this role effective June 26, 2023, replacing Mick Ruxin, M.D., who will transition to Theralink’s Chief Medical Officer.お知らせ • May 24Theralink Technologies, Inc. (OTCPK:THER) entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. (NasdaqCM:BACK) in a reverse merger transaction.Theralink Technologies, Inc. (OTCPK:THER) entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. (NasdaqCM:BACK) in a reverse merger transaction on May 23, 2023. The Merger is structured as a stock for stock reverse merger whereby all of Theralink’s outstanding equity interests are to be exchanged for shares of IMAC common stock. Theralink stakeholders are expected to own approximately 85% of the combined company, and pre-merger IMAC equity holders are expected to own approximately 15% of the combined company, on a fully diluted basis, subject to certain adjustments provided for in the Merger Agreement. All current IMAC directors but one will resign effective upon the closing of the Merger, and the existing directors of Theralink shall be appointed to the board of IMAC, with Jeffrey Busch to serve as Chairman.The boards of directors of Theralink and IMAC have unanimously approved the Merger Agreement. Transaction is subject to satisfying certain closing conditions, including the completion of satisfactory due diligence by both parties and the receipt of shareholder approval by Theralink and IMAC. The merger is expected to close late in the third quarter or early in the fourth quarter of 2023. Joseph Gunnar & Co., LLC is serving as the exclusive financial advisor to IMAC Holdings, Inc. and Theralink Technologies, Inc. in connection with the Transaction. Olshan Frome Wolosky LLP is serving as legal counsel for IMAC Holdings, Inc. and K&L Gates is serving as legal counsel for Theralink Technologies, Inc.お知らせ • Feb 16Theralink Technologies, Inc. announced delayed 10-Q filingOn 02/15/2023, Theralink Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 10Theralink Technologies Appoints Michael Vallone as Senior Director of CommercializationTheralink Technologies announced the appointment of Michael Vallone as Senior Director of Commercialization. Mr. Vallone brings to the Theralink team extensive commercialization experience, well-suited to support the Company's commercialization launch efforts. Theralink's commercialization opportunity is significant, being the only US company with commercial RPPA technology that can potentially predict which FDA-approved drug is effective in each cancer. The Theralink test is breakthrough technology, protected by nine patents, which is the next step beyond genomics. Prior to Theralink, Mr. Vallone spent 15 years with an industry leader in the field of genetics, establishing a track record of success in both sales and leadership roles within the organization. He was involved with several key initiatives within the Oncology division, including new product launches, strategic business planning, detailed sales analytics, customer service and account executive development and promotion. Mr. Vallone has had continued commercial success throughout his career and is a four-time President Club winner, a six-time MVP award recipient, and earned multiple promotions due to his performance and outstanding contributions to the organization. In addition, Mr. Vallone has expansive understanding of managed care, having spent more than seven years working for one of the largest managed care companies in the country in the area of provider relations and contracting.お知らせ • Dec 07Theralink Technologies, Inc. Appoints Faith Zaslavsky, as President & Chief Operating Officer for its Precision Oncology CompanyTheralink Technologies, Inc. announced the appointment of Faith Zaslavsky, a seasoned genomics commercial leader, as its President & Chief Operating Officer effective December 5, 2022. The Company's Theralink test is breakthrough technology, protected by nine patents, which is the next step beyond genomics. Faith has most recently held the position of President of Oncology for a $150 million division of a life sciences company pioneering in the genomic space. Her responsibilities included overseeing all commercials functions which include leading Medical Services, Medical Affairs, National and Enterprise Accounts, and Sales & Marketing. Ms. Zaslavsky has spent 22 years leading and transforming teams, designing solutions for physicians to support care, and advocating for patients facing a journey with cancer. In previous roles she served as the General Manager of Oncology, National Sales Director, Regional Sales Director, Regional Managed Care Director, and Regional Area Manager. Ms. Zaslavsky's talents and expertise are in forming large high performing multifunctional teams, strategic planning, cross functional alignment designing impactful patient centric health system partnerships and delivering results through proper P&L management. Faith also serves on the Board of Directors for the American Society of Breast Surgeons Foundation as well as non-profit organizations focusing on children's development. She received her bachelor's degree in Business Administration from Washington State University.お知らせ • Nov 08Theralink Technologies, Inc. Appoints Mattia Cremona as Its Director of Its Biopharma LaboratoryTheralink Technologies, Inc. (Theralink or the Company) announced that it has appointed Dr. Mattia Cremona as its Director of its Biopharma Laboratory effective November 7, 2022. Dr. Cremona is a molecular biologist, with a specialty in translation oncology research. During his career, he has worked in several research hospitals in Europe and the US, most recently as a Research Fellow at the Royal College of Surgeons in Ireland (RCSI), where he established the first Reverse Phase Protein Array (RPPA) Platform. Dr. Cremona's research involves using proteomic high-throughput approaches to study the status of the proteins inside cancer cells and to highlight changes with normal cells that could explain why patients do not respond to therapy or develop resistance after an initial response. He has contributed articles to several leading peer-reviewed journals, including Cancer and The British Journal of Cancer. He has presented at many international conferences and his published research has been frequently cited. Dr. Cremona completed his PhD in Molecular Medicine at Universita' degli Studi di Milano in 2009.お知らせ • May 18Theralink Technologies, Inc. announced delayed 10-Q filingOn 05/17/2022, Theralink Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 07Theralink Technologies, Inc. Announces Board AppointmentsOn April 1, 2022, Board of Directors of Theralink Technologies, Inc. voted to appoint Danica Holley and Matthew M. Schwartz, M.D. to serve as members of the Board, effective April 4, 2022. Ms. Holley and Dr. Schwartz will serve as members of the Board until the next annual meeting of shareholders of the company or until his or her resignation or removal and otherwise until his or her successor is elected.お知らせ • Feb 16Theralink Technologies, Inc. announced delayed 10-Q filingOn 02/15/2022, Theralink Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 31Theralink Technologies, Inc. announced delayed annual 10-K filingOn 12/30/2021, Theralink Technologies, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 29Theralink® Technologies Announces Commencement of Testing on Its First PatientsTheralink® Technologies announced that it has begun the testing of its first patients with the Theralink's Reverse Phase Protein Array (RPPA) technology. Theralink's RPPA testing measures the direct activation state for dozens of drug targets at once potentially providing oncologists with key information about the patient's specific tumor. Theralink's unique assay is the only commercial LDT assay on the market that can measure the activation/phosphorylation state of dozens of drug targets directly from a tumor biopsy. The initial use for the Theralink assay for breast cancer is for patients with: Late Stage (stage III-IV) Triple Negative Breast Cancer; Late Stage (stage III-IV) HER2+ Breast Cancer; Late Stage (stage III-IV) ER+/HER2- Breast Cancer; Metastatic Breast Cancer and Inflammatory Breast Cancer. Theralink is now accepting patients' breast cancer tumor biopsies from all physicians across the US except those physicians located in New York and California, which will be accepted upon Clinical Laboratory Improvement Amendments (CLIA) certification from those two states. Theralink's patented RPPA testing is designed to provide new protein and phosphoprotein biomarkers through the direct and quantitative measurement of the expression levels of a protein drug target and pathways surrounding it. This testing gives physicians data-driven support to help them make decisions and help them enable new predictive protein biomarker-based therapy selection. Theralink can measure the activation state of key drug targets and signaling pathways within a microscopic quantity of tumor sample.お知らせ • Nov 17Theralink Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.STheralink Technologies announced its partnership with Perthera. The alliance will facilitate and accelerate access to Theralink's 32 phosphoprotein panel, the Theralink assay, across the U.S. for breast cancer patients. Theralink will be launching its Reverse Phase Protein Array (RPPA) based LDT this year. This unique assay is the world's only phosphoprotein panel LDT that directly measures the activation state of targets of over 100 precision therapeutics at once. Together, Theralink and Perthera will collaborate to provide the Theralink assay results to oncologists in an easy to interpret, "powered by Perthera" report for potentially improved insights into therapeutic options for the patient's care plan. Through this partnership, Perthera will develop and manage Theralink's observational registry trial, TRACE (Theralink Registry to Assess Comprehensive Effectiveness). Perthera will utilize its Precision Oncology Platform, and serve as a Clinical Research Organization (CRO), to establish and launch the participation of Oncology practices and hospitals in the observational study throughout the US, implement the TRACE protocol, and assist in the enrollment of patients. Theralink will also utilize Perthera's Therapeutic Intelligence Engine™ to deliver a highly differentiated clinical report for physicians to gain clinical decision support more effectively from the innovative Theralink assay. Theralink has established TRACE to determine clinical utility using three indicators: Frequency of Actionable Data, Therapy Selection based upon the Theralink Assay, and Outcomes. Demonstrating clinical utility will allow Theralink to apply for a reimbursement code to potentially obtain full reimbursement from 3rd party payors for patients. In TRACE, the Theralink assay will be assessed alongside commercially available NGS-based genomic assay results. In addition, all patients enrolled in TRACE will have access to Perthera's Precision Medicine Platform and proprietary report.お知らせ • Sep 30OncBioMune Pharmaceuticals, Inc. Announces Executive ChangesOncBioMune Pharmaceuticals, Inc. announced that Andrew Kucharchuk resigned from his position as acting chief financial officer, effective September 24, 2020. Mr. Kucharchuk will continue to serve as a director on the company's board of directors. Thomas E. Chilcott, III, age 52, has been appointed chief financial officer to serve effective September 24, 2020, until his resignation or removal by the company. Immediately prior to joining the Company, Mr. Chilcott was the President of Chilcott Consulting Group, a financial and accounting services firm specializing in corporate restructuring and turnaround management. Prior to Chilcott Consulting, from January 2017 to June 2019, Mr. Chilcott worked for Ampio Pharmaceuticals, Inc., a publicly-traded development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options, where from June 2017 through June 2019 he served as their Chief Financial Officer, Secretary and Treasurer. From 2006 to his time at Ampio, Mr. Chilcott was the President of Chilcott Consulting. He also worked in public accounting for KPMG Peat Marwick where he was an Audit Senior Manager.お知らせ • Sep 24OncBioMune Pharmaceuticals, Inc. announced that it expects to receive $2 million in fundingOncBioMune Pharmaceuticals, Inc. (OTCPK:OBMP) announced that it has entered into a securities purchase agreement with individual investor Doug Mergenthaler for private placement of 1,000 series E convertible preferred shares at a price of $2,000 per share for $2,000,000 on September 16, 2020. The series E preferred stock has a stated value of $2,000 per share and shall accrue, on a quarterly basis in arrears, dividends at the rate of 8% per annum on the stated value. The dividends shall be paid quarterly at the option of the holder in either cash or shares. The series E preferred shares is convertible at any time after the date that is two days after the filing of an amendment to the company’s certificate of incorporation with the Secretary of State of the State of Nevada to increase the company’s authorized common shares to 12,000,000,000. The number of shares of common stock issuable up on conversion is determined by dividing the stated value of the number of shares being converted, plus any accrued and unpaid dividends, by the lesser of $0.00375 and 75% of the average closing price of shares during the prior five trading days; provided, however, the conversion price shall never be less than $0.0021 per share. The shares will be issued pursuant to exemption provided under Regulation D. The company has paid $30,000 as fees and expenses.お知らせ • Aug 19OncBioMune Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/18/2020, OncBioMune Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Theralink Technologies は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:THER - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20231-13-5-5N/A9/30/20231-31-6-6N/A6/30/20231-48-5-5N/A3/31/20231-55-6-6N/A12/31/20221-48-6-6N/A9/30/20221-13-6-5N/A6/30/20220-8-6-6N/A3/31/20220-7-5-5N/A12/31/20211-7-5-5N/A9/30/20211-7-5-5N/A6/30/20211-7-5-5N/A3/31/20210-7-5-5N/A12/31/20200-6-4-4N/A9/30/20200-5-4-3N/A6/30/20200-10N/AN/AN/A3/31/2020N/A-10-1-1N/A12/31/2019N/A-9-1-1N/A9/30/2019N/A-2-1-1N/A6/30/2019N/A-3-2-2N/A3/31/2019N/A-7-2-2N/A12/31/2018N/A6-2-2N/A9/30/2018N/A-2-2-2N/A6/30/2018N/A-7-2-2N/A3/31/2018N/A-3-2-2N/A12/31/2017N/A-15-2-2N/A9/30/2017N/A-9N/A-2N/A6/30/2017N/A-4N/A-2N/A3/31/2017N/A-4N/A-2N/A12/31/2016N/A-2N/A-2N/A9/30/2016N/A-2N/A-2N/A6/30/2016N/A-2N/A-1N/A3/31/2016N/A-1N/A-1N/A12/31/2015N/A-1N/A-1N/A9/30/201500N/A0N/A6/30/201500N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: THERの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: THERの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: THERの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: THERの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: THERの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: THERの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 19:21終値2026/05/14 00:00収益2023/12/31年間収益2023/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Theralink Technologies, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 16Theralink Technologies Files Form 15Theralink Technologies, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.0001 per share.
お知らせ • Feb 16Theralink Technologies, Inc. announced delayed 10-Q filingOn 02/15/2024, Theralink Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 04Theralink Technologies, Inc. Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor BoardTheralink Technologies, Inc. announced that their long-standing, strategic partnership with the Inova Schar Cancer Institute is beginning to deliver promising results by way of assessing the feasibility and impact of the actionable information provided by the Theralink assay into Inova's Molecular Tumor Board (MTB)-based treatment decisioning making for cancer patients. The partnership involves the integration of the Theralink assay, protected by ten patents, into Inova's molecular tumor board's operational workflow. Over the past year, Inova has undertaken a feasibility study to develop and implement the procedures and infrastructure necessary for proteomic analysis within the context of the Inova Schar Molecular Tumor Board. The Theralink assay provides a direct means of determining the actionability of genomic derangements identified, as well as directly measuring the activation/elevation of protein drug targets otherwise missed by genomic analysis alone. Thus, the incorporation of key phosphoprotein and protein data generated by Theralink's RPPA technology into the Inova MTB could synergize with current genomics analysis to produce more accurate treatment selection and patient-tailored therapy regimes. Interim results of this pan-tumor study were presented at the 2023 ASCO Conference in Chicago. Specifically, the analysis examined the feasibility of incorporating laser capture microdissection (LCM) enrichment of tumor specimens and reverse phase protein array (RPPA) analysis with next generation sequencing (NGS) into a molecular tumor board for improving selection of targeted cancer therapy. Integrated review of the RPPA and NGS data by the MTB supported a clinical recommendation change for over half of the patients overall. Further, the proteomics data from the Theralink assay provided additional treatment considerations for 59% of the patients, the outcomes for whom continue to be monitored. Moreover, the collaboration with Inova and their MTB resulted in a recent finding1 wherein the Theralink proteomics data revealed a specific mechanism of resistance and likely lack of benefit to a targeted therapy being considered by the MTB for a patient with a rare form of inflammatory myofibroblastic cancer. Lastly, Inova and Theralink presented the results of another important study at ASCO 2023 that focused on Theralink's unique ability to quantitatively measure HER2 abundance and activation and found that nearly 50% of pancreatic tumor actually express moderate amounts of HER2 protein, which could be missed by existing commercial HER2 assays. While HER2 expression is not routinely evaluated in clinical practice for pancreatic cancer these results may have clinical implications, especially as new classes of HER2 antibody drug conjugates are considered for patients with HER2 non amplified tumors across organ sites. Theralink and Inova will update findings and results post study completion. Published results are anticipated in early 2024.
お知らせ • Aug 17Theralink Technologies, Inc. announced delayed 10-Q filingOn 08/15/2023, Theralink Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 28+ 1 more updateTheralink Technologies, Inc. Appoints Mick Ruxin as Chief Medical OfficerTheralink Technologies, Inc. announced the appointment of Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company’s President and Chief Operating Officer since December 2022, will assume this role effective June 26, 2023, replacing Mick Ruxin, M.D., who will transition to Theralink’s Chief Medical Officer.
お知らせ • May 24Theralink Technologies, Inc. (OTCPK:THER) entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. (NasdaqCM:BACK) in a reverse merger transaction.Theralink Technologies, Inc. (OTCPK:THER) entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. (NasdaqCM:BACK) in a reverse merger transaction on May 23, 2023. The Merger is structured as a stock for stock reverse merger whereby all of Theralink’s outstanding equity interests are to be exchanged for shares of IMAC common stock. Theralink stakeholders are expected to own approximately 85% of the combined company, and pre-merger IMAC equity holders are expected to own approximately 15% of the combined company, on a fully diluted basis, subject to certain adjustments provided for in the Merger Agreement. All current IMAC directors but one will resign effective upon the closing of the Merger, and the existing directors of Theralink shall be appointed to the board of IMAC, with Jeffrey Busch to serve as Chairman.The boards of directors of Theralink and IMAC have unanimously approved the Merger Agreement. Transaction is subject to satisfying certain closing conditions, including the completion of satisfactory due diligence by both parties and the receipt of shareholder approval by Theralink and IMAC. The merger is expected to close late in the third quarter or early in the fourth quarter of 2023. Joseph Gunnar & Co., LLC is serving as the exclusive financial advisor to IMAC Holdings, Inc. and Theralink Technologies, Inc. in connection with the Transaction. Olshan Frome Wolosky LLP is serving as legal counsel for IMAC Holdings, Inc. and K&L Gates is serving as legal counsel for Theralink Technologies, Inc.
お知らせ • Feb 16Theralink Technologies, Inc. announced delayed 10-Q filingOn 02/15/2023, Theralink Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 10Theralink Technologies Appoints Michael Vallone as Senior Director of CommercializationTheralink Technologies announced the appointment of Michael Vallone as Senior Director of Commercialization. Mr. Vallone brings to the Theralink team extensive commercialization experience, well-suited to support the Company's commercialization launch efforts. Theralink's commercialization opportunity is significant, being the only US company with commercial RPPA technology that can potentially predict which FDA-approved drug is effective in each cancer. The Theralink test is breakthrough technology, protected by nine patents, which is the next step beyond genomics. Prior to Theralink, Mr. Vallone spent 15 years with an industry leader in the field of genetics, establishing a track record of success in both sales and leadership roles within the organization. He was involved with several key initiatives within the Oncology division, including new product launches, strategic business planning, detailed sales analytics, customer service and account executive development and promotion. Mr. Vallone has had continued commercial success throughout his career and is a four-time President Club winner, a six-time MVP award recipient, and earned multiple promotions due to his performance and outstanding contributions to the organization. In addition, Mr. Vallone has expansive understanding of managed care, having spent more than seven years working for one of the largest managed care companies in the country in the area of provider relations and contracting.
お知らせ • Dec 07Theralink Technologies, Inc. Appoints Faith Zaslavsky, as President & Chief Operating Officer for its Precision Oncology CompanyTheralink Technologies, Inc. announced the appointment of Faith Zaslavsky, a seasoned genomics commercial leader, as its President & Chief Operating Officer effective December 5, 2022. The Company's Theralink test is breakthrough technology, protected by nine patents, which is the next step beyond genomics. Faith has most recently held the position of President of Oncology for a $150 million division of a life sciences company pioneering in the genomic space. Her responsibilities included overseeing all commercials functions which include leading Medical Services, Medical Affairs, National and Enterprise Accounts, and Sales & Marketing. Ms. Zaslavsky has spent 22 years leading and transforming teams, designing solutions for physicians to support care, and advocating for patients facing a journey with cancer. In previous roles she served as the General Manager of Oncology, National Sales Director, Regional Sales Director, Regional Managed Care Director, and Regional Area Manager. Ms. Zaslavsky's talents and expertise are in forming large high performing multifunctional teams, strategic planning, cross functional alignment designing impactful patient centric health system partnerships and delivering results through proper P&L management. Faith also serves on the Board of Directors for the American Society of Breast Surgeons Foundation as well as non-profit organizations focusing on children's development. She received her bachelor's degree in Business Administration from Washington State University.
お知らせ • Nov 08Theralink Technologies, Inc. Appoints Mattia Cremona as Its Director of Its Biopharma LaboratoryTheralink Technologies, Inc. (Theralink or the Company) announced that it has appointed Dr. Mattia Cremona as its Director of its Biopharma Laboratory effective November 7, 2022. Dr. Cremona is a molecular biologist, with a specialty in translation oncology research. During his career, he has worked in several research hospitals in Europe and the US, most recently as a Research Fellow at the Royal College of Surgeons in Ireland (RCSI), where he established the first Reverse Phase Protein Array (RPPA) Platform. Dr. Cremona's research involves using proteomic high-throughput approaches to study the status of the proteins inside cancer cells and to highlight changes with normal cells that could explain why patients do not respond to therapy or develop resistance after an initial response. He has contributed articles to several leading peer-reviewed journals, including Cancer and The British Journal of Cancer. He has presented at many international conferences and his published research has been frequently cited. Dr. Cremona completed his PhD in Molecular Medicine at Universita' degli Studi di Milano in 2009.
お知らせ • May 18Theralink Technologies, Inc. announced delayed 10-Q filingOn 05/17/2022, Theralink Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 07Theralink Technologies, Inc. Announces Board AppointmentsOn April 1, 2022, Board of Directors of Theralink Technologies, Inc. voted to appoint Danica Holley and Matthew M. Schwartz, M.D. to serve as members of the Board, effective April 4, 2022. Ms. Holley and Dr. Schwartz will serve as members of the Board until the next annual meeting of shareholders of the company or until his or her resignation or removal and otherwise until his or her successor is elected.
お知らせ • Feb 16Theralink Technologies, Inc. announced delayed 10-Q filingOn 02/15/2022, Theralink Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 31Theralink Technologies, Inc. announced delayed annual 10-K filingOn 12/30/2021, Theralink Technologies, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 29Theralink® Technologies Announces Commencement of Testing on Its First PatientsTheralink® Technologies announced that it has begun the testing of its first patients with the Theralink's Reverse Phase Protein Array (RPPA) technology. Theralink's RPPA testing measures the direct activation state for dozens of drug targets at once potentially providing oncologists with key information about the patient's specific tumor. Theralink's unique assay is the only commercial LDT assay on the market that can measure the activation/phosphorylation state of dozens of drug targets directly from a tumor biopsy. The initial use for the Theralink assay for breast cancer is for patients with: Late Stage (stage III-IV) Triple Negative Breast Cancer; Late Stage (stage III-IV) HER2+ Breast Cancer; Late Stage (stage III-IV) ER+/HER2- Breast Cancer; Metastatic Breast Cancer and Inflammatory Breast Cancer. Theralink is now accepting patients' breast cancer tumor biopsies from all physicians across the US except those physicians located in New York and California, which will be accepted upon Clinical Laboratory Improvement Amendments (CLIA) certification from those two states. Theralink's patented RPPA testing is designed to provide new protein and phosphoprotein biomarkers through the direct and quantitative measurement of the expression levels of a protein drug target and pathways surrounding it. This testing gives physicians data-driven support to help them make decisions and help them enable new predictive protein biomarker-based therapy selection. Theralink can measure the activation state of key drug targets and signaling pathways within a microscopic quantity of tumor sample.
お知らせ • Nov 17Theralink Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.STheralink Technologies announced its partnership with Perthera. The alliance will facilitate and accelerate access to Theralink's 32 phosphoprotein panel, the Theralink assay, across the U.S. for breast cancer patients. Theralink will be launching its Reverse Phase Protein Array (RPPA) based LDT this year. This unique assay is the world's only phosphoprotein panel LDT that directly measures the activation state of targets of over 100 precision therapeutics at once. Together, Theralink and Perthera will collaborate to provide the Theralink assay results to oncologists in an easy to interpret, "powered by Perthera" report for potentially improved insights into therapeutic options for the patient's care plan. Through this partnership, Perthera will develop and manage Theralink's observational registry trial, TRACE (Theralink Registry to Assess Comprehensive Effectiveness). Perthera will utilize its Precision Oncology Platform, and serve as a Clinical Research Organization (CRO), to establish and launch the participation of Oncology practices and hospitals in the observational study throughout the US, implement the TRACE protocol, and assist in the enrollment of patients. Theralink will also utilize Perthera's Therapeutic Intelligence Engine™ to deliver a highly differentiated clinical report for physicians to gain clinical decision support more effectively from the innovative Theralink assay. Theralink has established TRACE to determine clinical utility using three indicators: Frequency of Actionable Data, Therapy Selection based upon the Theralink Assay, and Outcomes. Demonstrating clinical utility will allow Theralink to apply for a reimbursement code to potentially obtain full reimbursement from 3rd party payors for patients. In TRACE, the Theralink assay will be assessed alongside commercially available NGS-based genomic assay results. In addition, all patients enrolled in TRACE will have access to Perthera's Precision Medicine Platform and proprietary report.
お知らせ • Sep 30OncBioMune Pharmaceuticals, Inc. Announces Executive ChangesOncBioMune Pharmaceuticals, Inc. announced that Andrew Kucharchuk resigned from his position as acting chief financial officer, effective September 24, 2020. Mr. Kucharchuk will continue to serve as a director on the company's board of directors. Thomas E. Chilcott, III, age 52, has been appointed chief financial officer to serve effective September 24, 2020, until his resignation or removal by the company. Immediately prior to joining the Company, Mr. Chilcott was the President of Chilcott Consulting Group, a financial and accounting services firm specializing in corporate restructuring and turnaround management. Prior to Chilcott Consulting, from January 2017 to June 2019, Mr. Chilcott worked for Ampio Pharmaceuticals, Inc., a publicly-traded development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options, where from June 2017 through June 2019 he served as their Chief Financial Officer, Secretary and Treasurer. From 2006 to his time at Ampio, Mr. Chilcott was the President of Chilcott Consulting. He also worked in public accounting for KPMG Peat Marwick where he was an Audit Senior Manager.
お知らせ • Sep 24OncBioMune Pharmaceuticals, Inc. announced that it expects to receive $2 million in fundingOncBioMune Pharmaceuticals, Inc. (OTCPK:OBMP) announced that it has entered into a securities purchase agreement with individual investor Doug Mergenthaler for private placement of 1,000 series E convertible preferred shares at a price of $2,000 per share for $2,000,000 on September 16, 2020. The series E preferred stock has a stated value of $2,000 per share and shall accrue, on a quarterly basis in arrears, dividends at the rate of 8% per annum on the stated value. The dividends shall be paid quarterly at the option of the holder in either cash or shares. The series E preferred shares is convertible at any time after the date that is two days after the filing of an amendment to the company’s certificate of incorporation with the Secretary of State of the State of Nevada to increase the company’s authorized common shares to 12,000,000,000. The number of shares of common stock issuable up on conversion is determined by dividing the stated value of the number of shares being converted, plus any accrued and unpaid dividends, by the lesser of $0.00375 and 75% of the average closing price of shares during the prior five trading days; provided, however, the conversion price shall never be less than $0.0021 per share. The shares will be issued pursuant to exemption provided under Regulation D. The company has paid $30,000 as fees and expenses.
お知らせ • Aug 19OncBioMune Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/18/2020, OncBioMune Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.